FDA Urged To Improve “Predictability” For Orphan Drugs By Social Security Head Astrue
This article was originally published in The Pink Sheet Daily
Executive Summary
Commissioner Hamburg urged to set regular briefings on orphan drug development. Policy at the top doesn’t always translate into the “trenches,” former TKT CEO says.
You may also be interested in...
SSA Seeks Industry Help In Speeding Coverage For Orphan Drugs
Sponsors of drugs to treat disabling illnesses have an opportunity to work with the Social Security Administration to simplify eligibility determinations that could in turn make it easier for patients to obtain Medicare coverage for their treatments.
SSA Seeks Industry Help In Speeding Coverage For Orphan Drugs
Sponsors of drugs to treat disabling illnesses have an opportunity to work with the Social Security Administration to simplify eligibility determinations that could in turn make it easier for patients to obtain Medicare coverage for their treatments.
Shire Adds Two Pipeline Products With TKT Acquisition
Shire's acquisition of Transkaryotic Therapies will bring the company one Hunter Syndrome therapy candidate and one Gaucher disease therapy candidate